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Angiotensin II induces superoxide anion production by mesangial
cells.
Background. The recognized role of angiotensin II (Ang II) in
the pathogenesis of the progression of renal disease cannot be
solely attributed to Ang II’s hemodynamic effects. Indeed, growth
stimulating signals driven by Ang II promote mesangial cell (MC)
hypertrophy and extracellular matrix production, prominent fea-
tures of progressive glomerular injury. Superoxide anion (O2
2)
avidly interacts with nitric oxide, an endogenous vasodilator that
inhibits growth factor stimulated MC growth and matrix produc-
tion. In addition, O2
2 acting as an intracellular signal is linked to
growth related responses such as activation of mitogen activated
protein (MAP) kinases. The studies reported herein were de-
signed to investigate: (a) whether Ang II induces MC O2
2
production and (b) if increased O2
2 production elicits growth
responses in MC.
Methods. MC were exposed to Ang II for 24 or 48 hours. In
some experiments, in addition to Ang II, MC were exposed to:
diphenylenieodonium (DPI), an inhibitor of the flavin containing
NADH/NADPH oxidase; losartan (LOS), an Ang II type 1 (AT1)
receptor blocker; PD 98059, a MAP kinases inhibitor; the protein
kinase C inhibitors Calphostin C or H-7; and the tyrosine kinase
inhibitors, herbymycin A or genistein.
Results. Ang II (1025 M to 1028 M) dose dependently increased
MC O2
2 production up to 125% above control (ED 50 5 3 1027
M). LOS as well as DPI, and the PKC inhibitors blocked Ang II
stimulated MC O2
2production. Ang II dose dependently in-
creased MC 3H-leucine incorporation, and MC protein content,
two markers of MC hypertrophy, as well as 3H-thymidine incor-
poration, a marker of MC hyperplasia. PD98059, a specific
inhibitor of MAP kinases prevented Ang II induced MC hyper-
trophy. Moreover, LOS, DPI, and the PKC inhibitors each
independently inhibited MC 3H-leucine incorporation, thereby
establishing the specificity of Ang II induced O2
2 in driving MC
hypertrophy.
Conclusions. The current studies demonstrate a previously
unrecognized link between Ang II and MC O2
2 production that
may participate in the pathophysiology of progressive renal dis-
ease by concomitantly affecting the hemodynamics of the glomer-
ular microcirculation as well as growth related responses of MC to
injury.
The glomerular mesangium, which is composed of mes-
angial cells (MC) and extracellular matrix, occupies the
centrolobular area of the glomerulus, and also extends
outward a short distance into the capillary wall [1]. The
endothelial cell lining of the glomerulus is strategically
situated at the interface between the blood and the mes-
angium, without interposition of the glomerular basement
membrane. In this location, endothelial cells serve as direct
sensors and transducers of physical and biochemical signals
within the microenvironment of the glomerulus [1]. Due to
the direct juxtaposition of endothelial cells and MC, prod-
ucts synthesized by one of these cells can reach the other in
high concentrations with minimal inactivation or dilution
by circulating plasma [2]. In addition, the intrarenal con-
centration of Ang II is up to 1000-fold higher than in the
serum [3]. MC contain actin-myosin filaments that alter
their contractile state in response to vasoactive agents
acting in an autocrine and/or paracrine fashion [4]. Thus,
Ang II, eicosanoids, endothelin-1 and nitric oxide (NO)
synthesized and released locally, modulate the glomerular
microcirculation during physiologic and pathologic condi-
tions by acting upon the mesangium as well as the afferent
and efferent arterioles [5]. Moreover, similar to what
occurs in systemic vascular beds, these vasoactive agents
may also affect the response of glomerular cells to injury
and promote architectural changes, such as mesangial
hypertrophy and/or hyperplasia [6, 7], as well as increased
MC matrix production [8]. In this context Ang II modulates
MC synthesis of growth factors including platelet-derived
growth factor (PDGF) [9] and transforming growth fac-
tor-b (TGF-b) [8], which have been incriminated in the
pathological remodeling of the glomerulus in response to
injury [10].
Upregulation of the local tissue renin angiotensin system
(RAS) in response to injury has been shown in a variety of
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renal diseases [11]. Furthermore, in many patients with
chronic renal failure, blockade of the RAS with angiotensin
converting enzyme (ACE) inhibitors slows the decline of
renal function [12–15]. These effects of inhibition of the
RAS are in addition to, but independent of blood pressure
control [13, 15]. These clinical studies as well as a large
number of in vivo [16, 17] and in vitro [8, 18] experimental
studies support the notion that the nonhemodynamic ef-
fects of Ang II are pathophysiologically important in pro-
gressive glomerular injury. Thus, further understanding of
these mechanisms is necessary for the development of new
therapeutic strategies.
MC are endowed with a NADH/NADPH oxidase, a
flavin containing oxidase, whose components are antigeni-
cally related but not identical to that of phagocytes [19, 20].
Recent studies demonstrated that Ang II activates NADH/
NADPH oxidase in vascular smooth muscle cells resulting
in synthesis of superoxide anion (O2
2) [21, 22]. The
vascular smooth muscle cell NADH/NADPH oxidase is
structurally different from that present in leukocytes; in
addition it produces quantitatively less O2
2, but for a much
longer period of time [21]. O2
2 is a powerful intracellular
signal for the activation of responses linked to mitogen
activated protein (MAP) kinases-driven cell growth [23],
particularly cell hypertrophy [21]. Increased O2
2 in the
extracellular milieu, given its great affinity for NO, rapidly
interacts with this molecule and results in NO inactivation
and/or production of toxic peroxynitrite [24]. Within the
glomerulus a decrease in NO bioactivity: (a) would curtail
the capacity of NO to counteract Ang II actions on
mesangial contraction and arteriolar tone, and (b) would
reduce the homeostatic role of NO in antagonizing Ang II
driven growth related processes affecting MC and extracel-
lular matrix as well as preventing platelet and leukocyte
adhesion to the endothelium [5]. Heretofore no data are
available regarding whether Ang II can activate MC
NADH/NADPH oxidase and promote O2
2 synthesis.
Given the potential pathophysiologic and therapeutic
implications linked to increased MC O2
2 production within
the glomerular microcirculation is that we designed studies
aimed at elucidating whether Ang II activates MC NADH/
NADPH oxidase, as well as the mechanism(s) involved and
its relationship with MC hypertrophy and/or hyperplasia.
METHODS
Materials
Ang II, lucigenin, xanthine, xanthine oxidase, herbimycin
A, genistein, H-7 and calphostin C were purchased form
Sigma Chemical Co. (St. Louis, MO, USA); 3H-leucine and
3H-thymidine were purchased from Amersham Life Sci-
ence (Little Chalfont, UK); diphenylenieodinium (DPI)
was purchased from Toronto Research Chemicals (Toron-
to, Canada). LOS was kindly provided by Dupont Merck
(Wilmington, DE, USA). PD98059 was purchased from
Park Davis (Ann Arbor, MI, USA).
Rat mesangial cells culture
Primary MC cultures were prepared from male Sprague-
Dawley rats as previously described [25]. Cells were grown
using techniques that yield macrophage-free homogenous
cultures, as previously characterized [26]. Cells were grown
in RPMI-1640 media (Gibco Laboratories, Grand Island,
NY, USA) supplemented with 17% heat-inactivated fetal
calf serum (FCS; Hyclone Laboratories, Logan, UT, USA),
100 U ml penicillin, 100 mg/ml streptomycin, 15 mM
HEPES, 10 ml/liter insulin-transferrin-selenium supple-
ment (Sigma Chemical Co.). Cells were passed by
trypsinization when confluent, and used between the third
and ninth passages. Cells were grown in either six-well
dishes or 75 cm2 flasks (see below).
Measurement of O2
2 anion production
O2
2 production was determined by chemiluminescence
of lucigenin, an acridylium dinitrate compound that emits
light on reduction and interaction with O2
2 [27]. Briefly,
MC grown in 75 cm2 flasks were made quiescent in RPMI
1640 with 0.5% FCS for 72 hours and exposed to Ang II
(1025 to 1028 M) for five hours. At the end of the incubation
period, MC were trypsinized, pelleted by centrifugation,
resuspended in 2 ml Krebs buffer and kept on ice until use.
A 50 ml aliquot was saved for protein determination. To
measure superoxide production cells suspensions were
incubated at room temperature for three minutes and then
added to a scintillation vial containing dark adapted lucige-
nin (250 mM) in 2 ml 100 mM phosphate buffer (pH 7.4).
Photon emission was measured every minute for 10 min-
utes in a scintillation counter in the out-of-coincidence
mode. A buffer blank was subtracted from each reading
and superoxide production calculated by comparison with a
standard curve generated using xanthine/xanthine oxidase
as described by Ohara et al [27]. Protein content was
determined by the Bio-Rad method (Hercules, CA, USA).
3H leucine incorporation
MC protein synthesis measured by 3H-leucine incorpo-
ration was used as an index of MC hypertrophy. MC cells
were grown in six well dishes, made quiescent in RPMI
1640 with 0.5% FCS for 72 hours. MC were then incubated
for 24 or 48 hours in the presence or absence of Ang II
(1028 to 1025 M). Six hours before harvesting MC were
pulsed with 3H-leucine 2 mCi/ml. At the end of this
incubation period, cells were washed three times with
phosphate buffered saline (PBS) and solubilized overnight
with 1.5 ml sodium dodecyl sulfate (SDS) 0.1%. The
content of two wells was pooled and transferred to a plastic
tube containing 60 ml 10% bovine serum albumin. Proteins
were precipitated with 300 ml 20% trichloroacetic acid
(TCA) and left overnight at 4°C. Samples were then spun at
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2,000 g 3 30 minutes, the supernatant discarded and pellet
resuspended in 0.5 N sodium hydroxide (NaOH). Duplicate
aliquots (0.5 ml) were removed and counted in a scintilla-
tion counter. Results were expressed as cpm/million cells.
Mesangial cell protein content
Mesangial cell total protein content was used as addi-
tional index of MC hypertrophy. MC were grown in six well
dishes, made quiescent in RPMI 1640 with 0.5% FCS for 72
hours. MC were then incubated for 48 hours in the
presence or abscence of Ang II (1025 M). At the end of the
incubation period MC were trypsinized, counted, and MC
total protein content determined by Bio-Rad (Hercules,
CA, USA). Results were expressed as mg protein/million
cells.
3H-thymidine incorporation
3H-thymidine incorporation by MC was used as an index
of MC proliferation. MC were grown in six well dishes, and
made quiescent in RPMI 1640–0.5% FCS for 72 hours.
MC were then incubated for 24 or 48 hours in the presence
or absence of Ang II (1025 M). Four hours before harvest-
ing, cells were pulsed with 3H-thymidine 1 mCi/ml. At the
end of this incubation period, cells were washed three times
with PBS. Protein precipitated with 1 ml TCA 10% for five
minutes and solubilized in 1 ml 0.5 N NaOH/0.1% SDS.
Duplicate aliquots (0.5 ml) were removed, neutralized with
50 ml 6 N hydrochloric acid and counted in a liquid
scintillation counter. Results were expressed as counts/
million cells.
Statistical analysis
Data are expressed as mean 6 SEM. For statistical
comparison involving two groups, an unpaired Student’s
t-test was used, while for comparison involving more than
two groups, ANOVA using the Statview 521 statistical
program was employed (Abacus Concepts, Inc., Berkeley,
CA, USA). Significance was considered present when P ,
0.05.
RESULTS
Angiotensin II induces superoxide production by MC
Mesangial cells exposed to Ang II (1028 M to 1025 M) for
five hours significantly increased (O2
2) production in a
dose dependent manner (Fig. 1). This increased O2
2 was
fully blocked with losartan (LOS) 1026 M, suggesting that
the effects of Ang II on superoxide production are medi-
ated through the AT1 receptor: Control, 84.01 6 5 nmol
O2
2/mg protein/min; Ang II 1025 M, 189.66 6 28.4 nmol
O2
2/mg protein/min; Ang II 10-5 M 1 LOS 1026 M, 80.71 6
24.24 nmol O2
2/mg protein/min; P , 0.05, Ang II versus
control and Ang II1LOS (Fig. 2).
To determine whether mesangial NADH/NADPH oxi-
dase activation was responsible for the Ang II-induced
superoxide production, MC were exposed for one hour to
the flavin containing oxidase inhibitor diphenyleneiodo-
nium (DPI) 1025 M, prior to Ang II stimulation. DPI
inhibited Ang II-induced superoxide production by MC
(Ang II 1025 M, 189.66 6 28.4 nmol O2
2/mg protein/min vs.
Ang II 1025 M 1 DPI 1025 M, 31.8 6 17.07 nmol O2
2/mg
protein/min; P , 0.05). As shown in Figure 2, DPI also
inhibited basal O2
2 production in unstimulated MC. Thus,
Ang II in a dose dependent manner induced O2
2 produc-
tion by MC, the process involved NADH/NADPH oxidase
activation, and was mediated through AT1 receptor activa-
tion (Fig. 2).
Fig. 1. Angiotensin II (Ang II) induces
superoxide (O2
2) production in a dose
dependent manner. Mesangial cells (MC) were
exposed to Ang II in the indicated
concentrations for five hours. MC O2
2
production was estimated 10 minutes after
exposure to lucigenin. Data represent the
mean 6 SEM of 3 to 6 experiments by duplicate.
*P , 0.05 versus control.
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Angiotensin II induces MC hypertrophy
Mesangial cells exposed to Ang II (1025 to 1028 M) for 48
hours increased protein synthesis in a dose dependent
manner as measured by 3H-leucine incorporation (Fig. 3).
Furthermore, Ang II (1025 M) increased total MC protein
content for 48 hours (Control, 221 6 26.52 mg protein/106
cells vs. Ang II 1025 M, 312 6 36.9 mg/106 cells; N 5 3, P ,
0.05). Treatment with LOS was not accompanied by in-
creased cell lethality as assessed by trypan blue exclusion
(trypan blue exclusion . 90%). LOS completely blocked
the effects of Ang II on 3H-leucine incorporation, therefore
suggesting that these effects were mediated by activation of
the AT1 receptor (Ang II 1025 M, 50871 6 1854 cpm/106
cells versus Ang II 1025 M 1 LOS 1026 M, 17849 6 526
cpm/106 cells, P , 0.05; Fig. 4). Ang II (1025 M) exposure
for 24 hours, however, did not significantly increase MC
3H-leucine incorporation (Control, 27839.44 6 1486 cpm/
106 cells versus Ang II 1025 M, 30813.99 6 1198 cpm/106
cells; N 5 3, P 5 NS).
NADH/NADPH oxidase activation, superoxide production
and MC hypertrophy
To determine whether NADH/NADPH oxidase activa-
tion can mediate MC hypertrophy in response to Ang II,
MC were exposed to the NADH/NADPH oxidase inhibitor
DPI (1025 M), for one hour prior to Ang II. Treatment with
Fig. 2. Effect of diphenylenieodonium (DPI)
and losartan (LOS) on antiotensin II (Ang II)
induced superoxide (O2
2) generation by
mesangial cells (MC). MC were exposed to the
inhibitor of flavin containing oxidases
diphenyleneiodonium (DPI) or the AT1
receptor blocker losartan (LOS), prior to Ang
II (1025 M). DPI, as well as LOS abolished MC
O2
2 production induced by Ang II. DPI also
inhibited O2
2 production in unstimulated MC.
Data represent the mean 6 SEM of 3
experiments by duplicate. *P , 0.05 versus all
other conditions; #P , 0.05 versus control.
Fig. 3. Ang II induces MC hypertrophy in a
dose dependent manner. MC were exposed to
the indicated Ang II concentrations for 48
hours. MC 3H leucine incorporation was used
as an index of MC hypertrophy. Data represent
the mean 6 SEM of 3 experiments by duplicate.
*P , 0.05 versus control.
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DPI was not accompanied by increased cell lethality as
assessed by trypan blue exclusion (trypan blue exclusion .
90%). DPI completely abolished MC increased protein
synthesis in response to Ang II, suggesting that the hyper-
trophic response to Ang II in MC is linked to NADH/
NADPH oxidase activation (Fig. 4). DPI also significantly
inhibited basal O2
2 production and 3H-leucine incorpora-
tion in unstimulated MC (Figs. 2 and 4). To determine
whether ROS scavengers can inhibit Ang II induced MC
hypertrophy, MC were exposed to the O2
2 scavenger
superoxide dismutase (SOD; 150 U/ml) prior to Ang II.
SOD, which does not penetrate cell membranes [28], did
not inhibit Ang II induced MC protein synthesis (Ang II
1025 M, 36077.8 6 5515.6 cpm/106 cells versus Ang II 1025
M 1 SOD 150 U/ml, 38193.8 6 7243 cpm/106 cells; N 5 3,
P 5 NS). O2
2 can dismutate either spontaneously or
through SOD to H2O2 [29]. We therefore exposed MC to
the H2O2 scavenger catalase (800 U/ml), an enzyme that
penetrates cell membranes [30], prior to Ang II. Catalase
blunted Ang II induced MC protein synthesis, therefore
suggesting that H2O2 probably generated by O2
2 dismuta-
tion contributes to the Ang II-induced MC hypertrophy
(Fig. 5).
Reactive oxygen species (ROS), including O2
2, have
been shown to induce MAP kinases activation [30–33], a
process that is associated with cell growth but does not
affect O2
2 production [18, 34]. MC were treated with the
specific MAP kinase kinase (MEK) inhibitor PD98059 (50
Fig. 4. LOS and DPI prevents MC 3H leucine
incorporation induced by Ang II. MC were
exposed for 48 hours to Ang II 1025 M in the
presence of LOS or DPI. MC 3H leucine
incorporation was used as an index of MC
hypertrophy. Data represent the mean 6 SEM
of 4 experiments by duplicate. *P , 0.05 versus
all other conditions; #P , 0.05 versus control.
Fig. 5. Catalase prevents MC 3H leucine
incorporation induced by Ang II. MC were
exposed for 48 hours to Ang II 1025 M in the
presence of catalase (800 U/ml). MC 3H leucine
incorporation was used as an index of MC
hypertrophy. Data represent the mean 6 SEM
of 3 experiments by duplicate. *P , 0.05 versus
all other conditions; #P , 0.05 versus control
and catalase.
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mM) one hour prior to Ang II stimulation. Treatment with
PD98059 was not accompanied by increased cell lethality as
assessed by trypan blue exclusion (trypan blue exclusion .
90%). MAP kinases inhibition completely prevented MC
3H-leucine uptake in response to Ang II (Ang II 1025 M,
50440.1 6 4125 cpm/106 cell vs. Ang II 1025 M 1 PD98059,
9031.78 6 1782.2 cpm/106 cells; N 5 4, P , 0.05), suggest-
ing that MAP kinases were involved in the hypertrophic
response to Ang II that was initiated by increased O2
2
production. Similar to what we observed with DPI,
PD98059 also inhibited basal MC 3H-leucine uptake in
unstimulated MC (Control, 11099.55 6 231 cpm/106 cells
versus PD98059, 4759.3 6 499 cpm/106 cells; N 5 3, P ,
0.05).
Angiotensin II induces MC O2
2 production and
hypertrophy by a PKC-mediated mechanism
Angiotensin II binding to the AT1 receptor induces
several transduction signals that lead ultimately to in-
creased intracellular Ca21 concentration [34] and protein
kinase C (PKC) activation [35]. PKC is involved in NADPH
activation in polymorphonuclear cells [36] and macro-
phages [37], however, its role in vascular or MC NADH/
NADPH oxidase activation has not been previously eluci-
dated. To determine whether PKC activation is involved in
Ang II induced O2
2 generation, MC were treated with the
highly specific PKC inhibitor calphostin C (1026 M) prior to
Ang II stimulation. Calphostin C significantly inhibited Ang
II induced O2
2 generation, suggesting that Ang II induced
O2
2 generation by MC involves a PKC mediated mecha-
nism (Ang II 1025 M, 265.9 6 52.8 nmol O2
2/mg protein/
min vs. Ang II 1025 M 1 calphostin C, 39.41 6 25.18 nmol
O2
2/min/mg; N 5 3, P , 0.05; Fig. 6). Furthermore, the
less specific PKC inhibitor H-7 (1025 M) also inhibited Ang
II stimulated MC O2
2 production (data not shown).
Hence, PKC activation is necessary for Ang II induced O2
2
generation in MC.
Accompanying the inhibitory effects on O2
2 production,
calphostin C (1026 M), completely inhibited 3H-leucine
incorporation in response to Ang II (Ang II 1025 M,
42807 6 8419 cpm/106 cells versus Ang II 1025 M 1
calphostin C 1026 M, 65.97 6 12 cpm/106 cells; N 5 3 P ,
0.05; Fig. 7). These results suggest that PKC activation is
necessary to induce O2
2 generation and the subsequent
MC hypertrophy in response to Ang II. Treatment with
calphostin C was not accompanied by increased cell lethal-
ity as assessed by trypan blue exclusion (trypan blue
exclusion . 90%); however, the extent of 3H-leucine
incorporation inhibition obtained with calphostin C was
substantially larger compared with DPI or PD98059. This
suggested that in addition to MC NADH/NADPH oxidase,
calphostin C may be inhibiting other PKC dependent
cellular processes involved in cell growth. In addition, in
separate experiments calphostin C also inhibited basal
3H-leucine incorporation in unstimulated MC (Control,
11099.5 6 230.5 cpm/106 cells vs. Control 1 calphostin C,
1339.2 6 160.9 cpm/106 cells; N 5 3, P , 0.05). Further-
more, the less specific PKC inhibitor H-7 (1025 M) also
significantly inhibited Ang II stimulated 3H-leucine incor-
poration (Ang II 1025 M, 36078.5 6 5515.5 cpm/106 cells vs.
Ang II 1 H-7, 7573.2 6 1914.8 cpm/106 cells; N 5 3, P ,
0.05).
It has been suggested that tyrosine kinase phosphoryla-
tion partially mediates the growth responses to Ang II in
VSMC [38]. However, in our studies, treatment with the
tyrosine kinase inhibitors herbimycin A (1026 M) for 18
hours or genistein (1025 M) for one hour prior to Ang II
(1025 M) did not inhibit Ang II-mediated O2
2generation by
MC, therefore indicating that tyrosine kinases activation is
not necessary for Ang II-mediated O2
2 generation by MC
Fig. 6. Calphostin C inhibits Ang II induced MC O2
2 production. MC
were exposed to the PKC inhibitor calphostin C (1 mM) prior to Ang II
1025 M. Data represent the mean 6 SEM of 3 experiments by
duplicate.*P , 0.05 versus all other conditions; #P , 0.05 versus control.
Fig. 7. Calphostin C prevents MC 3H leucine incorporation induced by
Ang II. MC were exposed for 48 hours to Ang II 1025 M in the presence
of the PKC inhibitor calphostin C (1 mM). MC 3H leucine incorporation
was used as an index of MC hypertrophy. Data represent the mean 6 SEM
of 3 experiments by duplicate. *P , 0.05 versus all other conditions; #P ,
0.05 versus control.
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[Ang II 1025 M, 253.18 6 60 nmol O2
2/mg protein/min
(N 5 6); Ang II 1 herbimycin A, 213 6 77 nmol O2
2/mg
protein/min (N 5 4); Ang II 1 genistein, 292 6 13 nmol
O2
2/mg protein/min (N 5 3); P 5 NS; Fig. 8).
Superoxide generation mediates angiotensin II induced
MC hyperplasia
Mesangial cells exposed to Ang II (1025 M) for 48 hours
increased MC proliferation measured by 3H-thymidine
incorporation (Control, 19579.2 6 1596.2 cpm/106 cells vs.
Ang II 1025 M, 28905.95 6 2410. 87 cpm/106 cells; N 5 3,
P , 0.05; Fig. 9). To determine whether NADH/NADPH
oxidase activation participates in MC hyperplasia in re-
sponse to Ang II, MC were exposed to the NADH/NADPH
oxidase inhibitor DPI (1025 M), for one hour prior to Ang
II. Treatment with DPI was not accompanied by increased
cell lethality as assessed by trypan blue exclusion (trypan
blue exclusion . 90%). DPI completely abolished Ang II
stimulated MC 3H-thymidine incorporation, suggesting
that the hyperplastic response to Ang II in MC is linked to
NADH/NADPH oxidase activation (Ang II 1025 M,
28,906 6 2411 cpm/106 cells vs. Ang II 1025 M 1 DPI,
909 6 152; N 5 3, P , 0.05; Fig. 9). MC exposure to Ang
II (1025 M) for 24 hours, however, did not increase 3H-
thymidine incorporation (Control, 13,069 6 1380 cpm/106
cells vs. Ang II 1025 M, 14,894 6 1920 cpm/106 cells; N 5 3,
P 5 NS).
DISCUSSION
These studies demonstrate that, to the best of our
knowledge for the first time, Ang II induces NADH/
NADPH oxidase-dependent O2
2 production by MC. The
effects of Ang II were blocked by the selective AT1
receptor blocker LOS as well as the NADH/NADPH
oxidase inhibitor, DPI. Current evidence suggests that
NADH/NADPH oxidase systems are an important source
of O2
2 in endothelial cells [27], vascular smooth muscle
cells (VSMC) [21] and MC [19]. Studies by Griendling and
Minieri have shown that Ang II activates NADH/NADPH
oxidase system in VSMC [21]. Our studies demonstrate a
similar effect to be initiated by Ang II in MC. Although all
the mechanisms that lead to NADH/NADPH activation by
Ang II in VSMC are not completely elucidated [21], it is
clear that specific binding to the AT1 receptor is necessary.
Binding of Ang II to the AT1 receptor is known to initiate
intracellular signaling responses that include G proteins,
phospholipase C, and adenylate cyclase, resulting in an
increase in 1,4,5-inositol triphosphate and diacylglycerol
[39], which ultimately results in increased intracellular
calcium concentration [34] as well as PKC activation [35].
PKC is involved in NADPH oxidase activation in inflam-
matory cells such as polymorphonuclear cells [36] and
macrophages [37], however, its role in MC NADH/
NADPH oxidase activation has not been previously stud-
ied. In the current studies, Ang II induced O2
2 generation
and MC hypertrophy were inhibited by PKC inhibitors,
thereby suggesting that in MC, NADH/NADPH oxidase
activation by Ang II is a PKC dependent process.
Ang II not only increases intracellular calcium and
activates PKC, but also stimulates some of the signal
transduction events activated by growth factors, including
protein-tyrosine phosphorylation [40], stimulation of c-fos
[41], and activation of mitogen-activated protein (MAP)
kinases [42, 43]. ERK1 and ERK2, the most well studied
MAP kinases, require phosphorylation of MEK to be
activated [44] and are involved in the early response to a
Fig. 8. Tyrosine kinase inhibition does not inhibit Ang II induced MC
O2
2 production. MC were exposed to the tyrosine kinase inhibitors
herbimycin (1 mM) or genistein (10 mM) prior to Ang II 1025 M. Neither
herbimycin nor genistein had a significant effect on Ang II induced MC
O2
2 production. Data represent the mean 6 SEM of 3 to 6 experiments by
duplicate. P 5 NS.
Fig. 9. DPI prevents MC 3H thymidine incorporation induced by Ang II.
MC were exposed for 48 hours to Ang II 1025 M in the presence of DPI.
MC 3H thymidine incorporation was used as an index of MC hyperplasia.
Data represent the mean 6 SEM of 3 experiments by duplicate. *P , 0.05
versus all other conditions; #P , 0.05 versus control.
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variety of stimuli involved in cellular growth [45], transfor-
mation and differentiation [46]. Studies from several labo-
ratories have shown that reactive oxygen species (ROS),
including O2
2 and hydrogen peroxide, are an important
intracellular signal for the activation of ERK1 and ERK2
[23], synthesis of growth factors [47, 48], and synthesis of
vasoactive agents [49]. Our results show that the specific
MEK inhibitor PD98059 inhibited MC hypertrophy in-
duced by Ang II, thereby suggesting that ERK1 and ERK2
activation is at a distal point of convergence along the
pathway triggered by the ROS generated by NADH/
NADPH oxidase, and which ultimately leads to MC hyper-
trophy. Whether similar intracellular signaling mechanisms
mediate Ang II-induced MC hyperplasia has not been
explored and it is beyond the scope of the current studies.
The tyrosine kinase inhibitors herbimycin A and
genistein did not inhibit Ang II induced O2
2 generation by
MC, therefore suggesting that in MC, Ang II activation of
NADH/NADPH oxidase is not tyrosine kinase dependent
[38].
Functional, biochemical and molecular biological studies
clearly support the existence of a local tissue RAS [50]. Ang
II concentration in several intrarenal compartments, in-
cluding the glomerulus, is 1000 times higher than those
found systemically [3], sustaining the notion that a local
tissue RAS can operate in the kidney in vivo and affect
renal function independently of systemic Ang II. In fact, in
the above described studies intrarenal Ang II was found to
be in concentrations similar to those used in our current in
vitro studies. Upregulation of the local tissue RAS in
response to injury has been demonstrated in a variety of
renal diseases including diabetes [12, 17]. In vivo transfec-
tion of human ACE into intact rat carotid arteries induces
vascular hypertrophy without modifying blood pressure or
serum ACE levels [47], thus suggesting that tissue RAS can
generate Ang II in concentrations sufficient to elicit VSMC
growth responses independently of hemodynamic changes
[50]. Of particular interest are recent studies that demon-
strate that NO modulates tissue ACE and in vivo inhibition
of NO synthesis increases vascular ACE content and activ-
ity, and promotes cardiac and vascular hypertrophy inde-
pendently of systemic blood pressure [51].
The current studies show that Ang II stimulates MC to
synthesize O2
2 in quantities similar to those reported and
which are known to be sufficient for reducing the bioactivity
of NO within the vascular wall in vivo and in vitro [22].
Within the glomerulus, the interaction of NO and Ang II
plays a pivotal role in mesangial regulation of glomerular
microcirculation [52]. Furthermore, it has become increas-
ingly clear that NO and Ang II have the capacity to induce
long-term changes in cell growth, with NO being a pro-
apoptotic and antiproliferative agent and Ang II antiapop-
totic [53] and stimulatory of cell growth via synthesis of O2
2
[21] and growth factors such as PDGF [9] and TGF-b [8].
Therefore, the antagonistic interaction between NO and
Ang II may play an important role in the modulation of the
structural changes that result as a consequence of the
glomerular response to injury in diseases such as hyperten-
sion and diabetes.
Clinically, ACE inhibitors do not achieve complete and
permanent suppression of plasma Ang II, which returns to
almost normal levels despite maintenance of ACE inhibitor
administration and effective control of systemic hyperten-
sion [54]. The mechanism(s) involved in the rebound of
plasma Ang II during ACE inhibition remain unclear and
may include Ang II synthesis via enzymes other than ACE
[54]. It is therefore reasonable to assume that the rebound
of Ang II levels would permit actions of Ang II at the tissue
level to remain pathophysiologically active. This may ex-
plain, at least in part, why in all clinical studies performed
thus far, blockade of the RAS with ACE inhibitors
achieved only a 50% risk reduction for decline in renal
failure [12–15].
In conclusion, the current studies demonstrate a previ-
ously unrecognized link between Ang II and MC superox-
ide production, due to NADH/NADPH oxidase activation.
Superoxide may participate in the pathophysiology of pro-
gressive renal disease by affecting the hemodynamics of the
glomerular microcirculation as well as growth related re-
sponses of MC to injury.
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APPENDIX
Abbreviations used in this article are: ACE, angiotensin converting
enzyme; Ang II, angiotensin II; AT1, angiotensin II type 1 receptor; DPI,
diphenyleneiodonium; H2O2, hydrogen peroxide; LOS, losartan; MC,
mesangial cell; MAP, mitogen activated protein; MEK, mitogen-activated
protein kinase kinase; NO, nitric oxide; O2
2, superoxide anion; PDGF,
platelet-derived growth factor; PKC, protein kinase C; RAS, renin-
angiotensin system; TGF-b, transforming growth factor b; VSMC, vascu-
lar smooth muscle cell.
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